Disruption of CD91 association with AXL and Fgr abrogates HSP-mediated signaling and cancer immunosurveillance
Trey Harkness, Abigail L. Sedlacek, Keya Shah, Alyssa M. Juergens, Joel Greenberger, Amitava Mukherjee, Robert J. Binder · 2025
Read Disruption of CD91 association with AXL and Fgr abrogates HSP-mediated signaling and cancer immunosurveillance by Trey Harkness, Abigail L. Sedlacek, Keya Shah, Alyssa M. Juergens, Joel Greenberger, Amitava Mukherjee, Robert J. Binder (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12698051.txt.
Description
Trey Harkness and co-authors study how a cell receptor helps the immune system spot cancer, in a paper from 2025. The receptor, called CD91, sits on immune cells that show threats to the rest of the system. It responds to heat shock proteins that carry bits of cancer cells.
The team asked how two partner proteins, named AXL and Fgr, help the receptor send signals. Computer models and gene edits showed that key sites on the receptor bind Fgr. Breaking those sites blocked signal flow and lowered immune signals. Mice that lacked Fgr in one immune cell type failed to control tumors well. Loss of AXL had a milder effect. The work names Fgr as the main partner in this guard role.
Catalog record
| CREATOR | Trey Harkness, Abigail L. Sedlacek, Keya Shah, Alyssa M. Juergens, Joel Greenberger, Amitava Mukherjee, Robert J. Binder |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |